Physician profile
Valentina Ruvalcaba
NPI 1669830451
$6,190.69
in general payments reported to CMS, 2019-2025
55 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 81% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,296 · 2022: $991 · 2023: $1,057 · 2024: $697 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,120 · Education: $617 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,120.42 |
| Education | $616.97 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $443.13 | 2021-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals Lp | $439.05 | 2022-2025 | Lynparza, Imfinzi |
| Janssen Biotech, INC. | $423.20 | 2021-2025 | Erleada, Rybrevant |
| Novartis Pharmaceuticals Corporation | $365.39 | 2023-2025 | |
| Pfizer INC. | $357.37 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $293.14 | 2021-2023 | Imbruvica, Epkinly |
| Seagen INC. | $235.33 | 2021-2025 | Adcetris |
| Aveo Pharmaceuticals, INC. | $183.12 | 2022-2025 | Fotivda |
| Celgene Corporation | $180.87 | 2022-2025 | Opdivo, Reblozyl, Opdualag |
| Daiichi Sankyo INC. | $173.29 | 2022-2025 | Enhertu, Injectafer |
| Eisai INC. | $168.97 | 2021-2025 | |
| Sobi, INC | $164.93 | 2024-2025 | |
| Amgen INC. | $158.24 | 2021-2022 | |
| Genzyme Corporation | $157.47 | 2021-2024 | |
| Glaxosmithkline, LLC. | $157.16 | 2021-2025 | Zejula, Jemperli, Blenrep |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valentina Ruvalcaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.